Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

1(16.7%)

Phase 3

1(16.7%)

6Total

Phase 1(4)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03038802Phase 1Not Yet Recruiting

A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection

Role: collaborator

NCT05807035Phase 1Recruiting

Autologous Tumour Vaccine Trial

Role: collaborator

NCT05279456Phase 3Completed

A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

Role: collaborator

NCT05148871Phase 2Active Not Recruiting

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

Role: collaborator

NCT02335164Phase 1Completed

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults

Role: collaborator

NCT03038776Phase 1Completed

Recombinant H7 Hemagglutinin Influenza Vaccine Trial

Role: collaborator

All 6 trials loaded